Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review
- 6 December 2022
- journal article
- review article
- Published by Taylor & Francis in Immunotherapy
- Vol. 14 (17) , 1361-1367
Abstract
Checkpoint inhibitor pneumonitis (CIP) is a relatively rare adverse event and a potential cause of death in patients treated with immune checkpoint inhibitors (ICIs). Because the symptoms and signs... Plain language summary We report a patient with advanced lung cancer who experienced shortness of breath induced by immunotherapy. The levels of nitric oxide from the exhaled breath in this case sh...Keywords
This publication has 34 references indexed in Scilit:
- Nivolumab-induced asthma in a patient with non-small-cell lung cancerAnnals of Oncology, 2017
- Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic reviewAnnals of Oncology, 2017
- Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung CancerChest, 2017
- Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisCancer Management and Research, 2017
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 TherapyJournal of Clinical Oncology, 2017
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced CancerJAMA Oncology, 2016
- Immune-mediated respiratory adverse events of checkpoint inhibitorsCurrent Opinion in Oncology, 2016
- The clinical value of exhaled nitric oxide in patients with lung cancerThe Clinical Respiratory Journal, 2016
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012
- Role of Nitric Oxide in Chronic Allergen-Induced Airway Cell Proliferation and InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2003